The Effect of Nitropaste in Chest Masculinizing Surgery: Randomized, Prospective Trial

What this Trial Is About

Researchers are evaluating nitropaste, a topical agent containing 2% nitroglycerin known for its vascular dilating effects, to see if it can reduce wound complications in patients undergoing chest masculinizing surgery using the double incision and free nipple grafting technique. This study is a prospective, randomized, single-blinded trial designed to explore nitropaste's potential benefits in this surgical context, as previous research has shown its positive effects on flap survival and wound healing in other procedures. Participants will be randomly assigned to one of two groups: one receiving the standard chest masculinizing surgery with standard dressings only, and the other receiving the same surgery plus a one-time intraoperative application of 30 mg nitropaste (15 mg on each chest) around the nipple graft and surgical sites. Both groups will have standard dressings applied, including a Xeroform bolster and Tegaderm, which they will keep until postoperative day 5 when the bolster is removed. During the study, participants will be followed up at 5 days, 2 weeks, and 6 weeks after surgery during routine postoperative visits. Researchers will assess the condition of free nipple grafts and other wounds as the primary outcomes. They will also monitor secondary outcomes such as complications, need for sharp debridement, revision surgeries, and hospital readmissions up to three months post-operation. The study will document any events including hematoma, seroma, infection, hypertrophic scarring, and emergency visits within 30 days.

Effect of Nitropaste in Chest Masculinizing Surgery